Company Overview - Supernus Pharmaceuticals (SUPN) currently holds a Momentum Style Score of B, indicating potential for strong performance based on recent trends [3] - The company has a Zacks Rank of 1 (Strong Buy), which is associated with a historical outperformance in the market [4] Price Performance - Over the past week, SUPN shares have increased by 5.3%, while the Zacks Medical - Generic Drugs industry has only risen by 0.77% [6] - In a longer time frame, SUPN's shares have shown an 11.26% monthly price change compared to the industry's 10.78% [6] - Over the past quarter, SUPN shares have surged by 41.67%, and over the last year, they have gained 54.65%, significantly outperforming the S&P 500, which increased by 8.19% and 19.61% respectively [7] Trading Volume - The average 20-day trading volume for SUPN is 711,004 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the last two months, two earnings estimates for SUPN have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $2.18 to $2.55 [10] - For the next fiscal year, two estimates have also moved upwards without any downward revisions [10] Conclusion - Considering the positive price trends, strong earnings outlook, and favorable trading volume, SUPN is positioned as a 1 (Strong Buy) stock with a Momentum Score of B, making it a compelling option for investors seeking short-term gains [12]

Core Insights - SUPN has shown significant growth with a revenue of $165 million in its second-quarter fiscal 2025 earnings report and has launched a new treatment for Parkinson's disease [1] - The stock has increased by 46% this year, indicating strong investor interest, particularly from institutional investors [2][3] - SUPN has a strong fundamental backdrop with an estimated EPS growth of +36.2% this year and a 1-year sales growth rate of +8.9% [4][6] Institutional Support - There has been strong institutional demand for SUPN, evidenced by unusual trading volumes and a history of outlier inflow signals [3][7] - The stock has been a top-rated pick at MoneyFlows for years, reflecting unusual buy pressure and growing fundamentals [5] Financial Performance - SUPN has demonstrated robust financial performance with a remarkable 3-year EPS growth rate of +1,792.4% [6] - The combination of strong fundamentals and significant money flows has historically led to substantial stock price increases [4][7] Price Prediction - Given the historical gains and strong fundamentals, SUPN is considered a potential candidate for a diversified investment portfolio [8]

Core Viewpoint - The market anticipates a year-over-year decline in Supernus Pharmaceuticals' earnings despite an increase in revenues when the company reports its quarterly results for the period ending September 2025 [1][3]. Earnings Expectations - Supernus is expected to report earnings of $0.47 per share, reflecting a significant year-over-year decrease of 55.7%. Revenue is projected to be $182.06 million, which is a 3.6% increase compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 14.29% higher in the last 30 days, indicating a reassessment by analysts of their initial estimates [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%. This suggests no recent differing analyst views from the consensus [12]. Historical Performance - In the last reported quarter, Supernus exceeded the expected earnings of $0.47 per share by delivering $0.91, resulting in a surprise of +93.62%. The company has beaten consensus EPS estimates in all of the last four quarters [13][14]. Investment Considerations - Despite the positive historical performance, Supernus does not appear to be a strong candidate for an earnings beat this time. Investors are advised to consider other factors beyond earnings results when making investment decisions [15][17].

Performance Overview - The Third Avenue Small-Cap Value Fund returned 7.18% in Q3 2025, underperforming the MSCI USA Small Cap Value Index at 8.97% and the Russell 2000 Value Index at 12.60% [2] - The Fund's annualized returns for the trailing three-year and five-year periods were 15.11% and 16.09%, respectively [2] Positive Contributors - Supernus Pharmaceuticals (SUPN) was the largest positive contributor, benefiting from a strong financial position, profitability, an expanding neurology drug portfolio, and a successful acquisition [3] - Investors Title Company (ITIC) saw positive performance due to increased real estate refinancing activity [3] - UMB Financial Corporation (UMBF) successfully integrated its acquisition of Heartland Financial, showcasing operational competence [3] Negative Contributors - Atlanta Braves Holdings (BATRA) was a negative contributor, though it is perceived to have an attractive asset base and potential for favorable resource conversion [4] - UniFirst Corporation (UNF) faced pressure to demonstrate its value proposition after rejecting an acquisition offer from Cintas Corporation (CTAS) [4] - FRP Holdings (FRPH) was impacted by a lack of confidence in government spending affecting the D.C. metro area [4] Investment Strategy - The Fund focuses on acquiring companies in transitional states, aiming to capitalize on undervalued businesses with potential for future growth [5] - Investment activity emphasizes companies that are well-financed, trading at discounts to net asset value, and have identifiable levers for value creation [6] - The Fund's turnover rate is approximately 20%, indicating a long-term investment horizon of about five years, contrasting with the average turnover of 91.7% in the small-cap value fund universe [7] Types of Investment Opportunities - The Fund identifies three broad types of investment opportunities: 1. Companies facing industry-wide headwinds that can improve through restructuring [9] 2. Companies with current economic returns that have underappreciated self-help opportunities [9] 3. Event-driven situations that offer unique return profiles through transformational changes [9] Recent Transactions - Ambac Financial (AMBC) completed the sale of its legacy financial guarantee business, leading to a significant cash inflow and a transformation towards insurance distribution [11][12] - The Fund initiated new positions in Boise Cascade (BCC) and Rogers Corporation (ROG) during the quarter, while also adding to existing positions like UniFirst Corporation (UNF) [14] Company Profiles - Boise Cascade is a leading manufacturer and distributor of building materials, facing challenges due to slowing housing activity but retaining a strong financial position [15][16] - Rogers Corporation specializes in electronic and materials technology solutions, facing growth challenges but possessing valuable intellectual property and a strong balance sheet [18][19][20]

Core Viewpoint - Supernus Pharmaceuticals (SUPN) has consistently exceeded earnings estimates and is well-positioned for future earnings growth, particularly with its upcoming quarterly report expected on November 4, 2025 [1][8]. Earnings Performance - In the last reported quarter, Supernus achieved earnings of $0.91 per share, significantly surpassing the Zacks Consensus Estimate of $0.47 per share, resulting in a surprise of 93.62% [2]. - For the previous quarter, the company reported earnings of $0.42 per share against an expectation of $0.38 per share, delivering a surprise of 10.53% [2]. Earnings Estimates and Predictions - Recent estimates for Supernus have been increasing, with a positive Earnings ESP (Expected Surprise Prediction) of +11.86%, indicating growing analyst optimism regarding its near-term earnings potential [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) suggests a high likelihood of another earnings beat in the upcoming report [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7].

[Form 8-K Filing Details](index=1&type=section&id=Form%208-K%20Filing%20Details) This section provides the foundational details of the Form 8-K filing, including registrant identification and filing specifics [Registrant Information](index=1&type=section&id=Registrant%20Information) This section provides the core identification details for Supernus Pharmaceuticals, Inc. as the registrant, including its incorporation state, commission file number, principal executive offices, and securities registered on Nasdaq - Registrant: **Supernus Pharmaceuticals, Inc.**[2](index=2&type=chunk) Registrant Details | Detail | Value | | :--- | :--- | | State of Incorporation | Delaware | | Commission File Number | 001-35518 | | I.R.S. Employer Identification No. | 20-2590184 | | Principal Executive Offices | 9715 Key West Ave, Rockville MD 20850 | | Registrant's Telephone Number | (301) 838-2500 | Registered Securities | Title of Class | Trading Symbol | Exchange | | :--- | :--- | :--- | | Common Stock, $0.001 par value per share | SUPN | The Nasdaq Stock Market LLC | [Filing Specifics](index=1&type=section&id=Filing%20Specifics) The report confirms the filing date and indicates that Supernus Pharmaceuticals, Inc. is not an emerging growth company - Date of Report (Date of earliest event reported): **October 21, 2025**[2](index=2&type=chunk) - The registrant is not an emerging growth company[3](index=3&type=chunk) [Current Report Items](index=2&type=section&id=Current%20Report%20Items) This section details the specific events reported in the Form 8-K, covering financial results and required exhibits [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Supernus Pharmaceuticals, Inc. announced its plan to release third-quarter 2025 business results and host a conference call and webcast on November 4, 2025, to discuss these financial and business outcomes - Supernus Pharmaceuticals, Inc. expects to report its **Q3 2025 business results** after market close on **Tuesday, November 4, 2025**[4](index=4&type=chunk) - A conference call and webcast will be held on **Tuesday, November 4, 2025, at 4:30 p.m. E.T.** to discuss the results[4](index=4&type=chunk) - A press release dated **October 21, 2025**, is furnished as **Exhibit 99.1**[4](index=4&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits filed with the Form 8-K, including the press release regarding Q3 2025 results and the Inline XBRL formatted cover page Exhibits Filed | Exhibit Number | Description | | :--- | :--- | | 99.1 | Press Release dated October 21, 2025 filed as an Exhibit pursuant to Item 2.02 hereof | | 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL | [Signatures](index=3&type=section&id=Signatures) This section confirms the official authorization and signatory details for the Form 8-K filing [Authorization and Signatory](index=3&type=section&id=Authorization%20and%20Signatory) The report was duly signed on behalf of Supernus Pharmaceuticals, Inc. by Timothy C. Dec, Senior Vice President and Chief Financial Officer, on October 21, 2025 - Report signed on behalf of **Supernus Pharmaceuticals, Inc.**[9](index=9&type=chunk) - Signatory: **Timothy C. Dec**, Senior Vice President and Chief Financial Officer[10](index=10&type=chunk) - Date of Signature: **October 21, 2025**[10](index=10&type=chunk)

Core Insights - Supernus Pharmaceuticals, Inc. is set to announce its third quarter 2025 financial and business results on November 4, 2025, after market close [1] - A conference call will be hosted by the President and CEO, Jack Khattar, and Senior Vice President and CFO, Tim Dec, on the same day at 4:30 p.m. ET to discuss the results [2] - The call will be accessible via a live webcast on the Company's Investor Relations website, with a replay available for 60 days post-call [3] Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for central nervous system (CNS) diseases [4] - The company's neuroscience portfolio includes treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [5]

Core Viewpoint - Supernus Pharmaceuticals (SUPN) is identified as a strong momentum stock with a Momentum Style Score of A and a Zacks Rank of 1 (Strong Buy), indicating potential for significant near-term gains [3][4][12]. Momentum Style Analysis - Momentum investing focuses on following a stock's recent price trends, with the aim of capitalizing on established price movements [1]. - The Zacks Momentum Style Score helps investors identify stocks with strong momentum characteristics, addressing the challenges of defining momentum [2]. Performance Metrics - Over the past week, SUPN shares increased by 2.81%, matching the performance of the Zacks Medical - Generic Drugs industry [6]. - In a longer timeframe, SUPN's monthly price change is 7.79%, significantly outperforming the industry's 0.5% [6]. - Over the past quarter, SUPN shares have surged by 51.51%, and over the last year, they have gained 48.49%, while the S&P 500 only increased by 4.67% and 14.71%, respectively [7]. Trading Volume - SUPN's average 20-day trading volume is 808,093 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - Recent earnings estimate revisions for SUPN show one upward revision for the full year, increasing the consensus estimate from $2.05 to $2.25 over the past 60 days [10]. - For the next fiscal year, there has been one upward revision with no downward revisions noted [10]. Conclusion - Given the strong performance metrics and positive earnings outlook, SUPN is positioned as a promising investment opportunity in the near term [12].

Core Viewpoint - Supernus Pharmaceuticals has shown strong stock performance, with a 36.9% increase year-to-date, significantly outperforming the Zacks Medical sector and the Zacks Medical - Generic Drugs industry [1][2]. Financial Performance - Supernus has consistently exceeded earnings expectations, reporting an EPS of $0.91 against a consensus estimate of $0.47 in its last earnings report [2]. - For the current fiscal year, Supernus is projected to achieve earnings of $2.24 per share on revenues of $696.95 million, reflecting a -28.34% change in EPS and a 5.31% change in revenues. The next fiscal year is expected to see earnings of $2.31 per share on revenues of $843.62 million, indicating a year-over-year change of 2.89% in EPS and 21.05% in revenues [3]. Valuation Metrics - Supernus currently trades at 22.1 times the current fiscal year EPS estimates, which is a premium compared to the peer industry average of 8.2 times. On a trailing cash flow basis, it trades at 11.9 times versus the peer group's average of 5.7 times [6]. Style Scores and Zacks Rank - Supernus has a Value Score of C, a Growth Score of C, and a Momentum Score of A, resulting in a VGM Score of B. The Zacks Rank for Supernus is 1 (Strong Buy), supported by favorable earnings estimate revisions from analysts [5][7].

Core Viewpoint - Supernus Pharmaceuticals (SUPN) is identified as a strong momentum stock with a Zacks Rank of 1 (Strong Buy) and a Momentum Style Score of B, indicating potential for significant near-term gains [4][12]. Company Performance - SUPN shares have increased by 1.28% over the past week, outperforming the Zacks Medical - Generic Drugs industry, which rose by 0.97% during the same period [6]. - Over the last month, SUPN's stock price has risen by 4.5%, compared to the industry's 1.4% [6]. - In the last quarter, SUPN shares have surged by 46.87%, and over the past year, they have gained 57.31%, significantly outperforming the S&P 500, which increased by 9.31% and 17.01% respectively [7]. Trading Volume - The average 20-day trading volume for SUPN is 645,479 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the past two months, two earnings estimates for SUPN have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from $1.50 to $2.18 [10]. - For the next fiscal year, two estimates have also moved upwards with no downward revisions [10].